Talquetamab Dose Modifications May Lower AEs While Maintaining Efficacy in R/R Multiple Myeloma

Dose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma.

Related Keywords

United States ,San Francisco ,California ,American ,Talquetamab Talvey ,Helen Diller Family Comprehensive Cancer Center ,American Society Of Hematology Annual Meeting ,University Of California ,Myeloma Program ,Hematology Annual ,Ajai Chari ,Multiple Myeloma Program ,Diller Family Comprehensive Cancer ,